Drug · DIN 02541823
COMIRNATY
MULTIDOSE VIAL
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since September 30, 2024; first marketed October 10, 2023.
- Drug Identification Number (DIN)
- 02541823
- Company (DIN owner)
- Biontech Manufacturing GmbhMainz, Rheinland-Pfalz, Germany
- Schedule
- Schedule D
- Dosage form
- Suspension
- Route
- Intramuscular
- Therapeutic class (ATC)
- COVID-19, RNA-based vaccine J07BN01
- Class
- Human
- Record last updated
- October 9, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| *SARSCOV2 S-PROTEIN MRNA, 5'[M27,3'-OGPPP(M12'-O)APG], 3'POLYA+LINKER | 30 MCG | 0.3 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- September 28, 2023: NOC 31809New Drug Submission (NDS)
Other DINs named COMIRNATY
- DIN 02541858 · Marketed
- DIN 02552035 · Marketed
- DIN 02509210 · Cancelled Post Market
- DIN 02522454 · Cancelled Post Market
- DIN 02527863 · Cancelled Post Market
- DIN 02530325 · Cancelled Post Market
- DIN 02552078 · Approved